Table 1.
Characteristics of thyroid disorders and COVID-19 outcomes related studies.
| Authors | Study Design | Samples | Male (%) | Age (years) | Hypertension (%) | CAD/CVD (%) | DM (%) | Obesity (%) | COPD (%) | Outcome | NOS |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Alqahtani et al., 2020 (12) | Retrospective cohort | 458 | 86.9 | N/A | 10.94 | 1.97 | 13.6 | 57.1 | N/A | Severity | 8 |
| Almazeedi et al., 2020 (13) | Retrospective cohort | 1096 | 81 | 41 | 16.1 | 4.3 | 14.1 | 21.8 | 0.5 | Severity | 6 |
| Baldelli et al., 2021 (14) | Retrospective cohort | 46 | 69.5 | 59.6 | N/A | N/A | N/A | N/A | N/A | ICU | 7 |
| Brix et al., 2021 (15) | Retrospective cohort | 16,502 | 45.6 | 57.3 | 26.73 | 17.35 | 11.96 | 10.9 | 5.8 | Mortality | 7 |
| Cao et al., 2020 (16) | Retrospective cohort | 198 | 51 | 50.1 | 21.2 | 6 | 7.6 | N/A | N/A | ICU | 7 |
| Daraei et al., 2020 (17) | Retrospective cohort | 390 | 67.7 | 58.1 | N/A | N/A | N/A | N/A | N/A | Mortality | 6 |
| Gao et al., 2020 (18) | Retrospective cohort | 100 | 52 | 62.3 | N/A | N/A | N/A | N/A | N/A | Severity and Mortality | 9 |
| Gong et al., 2021 (19) | Retrospective cohort | 150 | 54 | 69.8 | N/A | 11.33 | N/A | N/A | N/A | Mortality | 9 |
| Güven et al., 2021 (20) | Prospective cohort | 250 | 63 | 68 | N/A | N/A | N/A | N/A | N/A | ICU | 8 |
| Khoo et al., 2020 (21) | Prospective cohort | 334 | 60.8 | 66.1 | 48.5 | 23.7 | 39.5 | N/A | 17.4 | Mortality and ICU | 9 |
| Lang et al., 2021 (22) | Retrospective cohort | 127 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mortality | 7 |
| Lui et al., 2020 (23) | Prospective cohort | 191 | 51.8 | 53.5 | 27.2 | 6.3 | 13.1 | N/A | 3.1 | Severity | 8 |
| Muller et al., 2020 (24) | Prospective cohort | 145 | 61.3 | 66.9 | N/A | N/A | N/A | N/A | N/A | ICU | 6 |
| Sen et al., 2021 (25) | Prospective cohort | 60 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Severity | 6 |
| Shabrawishi et al., 2020 (26) | Retrospective cohort | 150 | 60 | 46.1 | 28.8 | 8 | 26 | N/A | 0.7 | Severity | 6 |
| Sisó-Almirall et al., 2020 (27) | Retrospective cohort | 322 | 50 | 56.7 | 33.9 | 7.8 | 14.3 | 14.3 | 5.9 | Hospitalization | 7 |
| van Gerwen et al., 2020 (28) | Retrospective cohort | 3703 | 55.3 | 56,9 | N/A | N/A | N/A | 57.4 | N/A | Hospitalization | 8 |
| Wang et al., 2020 (29) | Retrospective cohort | 84 | 63.1 | 57.3 | N/A | N/A | N/A | N/A | N/A | Severity | 9 |
| Zhang et al., 2020 (30) | Retrospective cohort | 140 | 50.7 | 56.3 | 30 | 7.1 | 12.1 | N/A | 1.4 | Severity | 7 |
| Zhang et al., 2020 (31) | Retrospective cohort | 71 | 56.3 | 62.7 | 28.2 | 21.1 | 18.3 | N/A | N/A | Severity and Mortality | 7 |
CAD/CVD: Coronary artery disease/cardiovascular disease; COPD: Chronic Obstructive Pulmonary Disease; DM: Diabetes Mellitus; HTN: Hypertension; N/A: Not applicable; NOS: Newcastle-Ottawa Scale.